Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lomecel-B for ARDS (COVID-19 or Influenza)
NCT04629105Phase 1Active, not recruiting
- Sponsor
- Longeveron
- Start
- Jul 2020
- Primary completion
- Jun 2024
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of laromestrocel in acute respiratory distress syndrome (ARDS) (4 cohorts), sponsored by Longeveron. Primary endpoints: Incidence of Treatment-Emergent Serious Adverse Events at 4 weeks, Number of Participants with Abnormal Clinical Significant Laboratory Values in Hematology at 6 months and 6 more. Started Jul 2020; status: active, not recruiting.
02
Drugs
laromestrocel
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04629105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04629105.